Dyno Therapeutics Forms New Strategic Partnership With Roche To Advance AAV Gene Therapy Vectors For Neurological Diseases
- New strategic partnership leverages the power of the Dyno platform, enabling Roche to advance next-generation AAV gene therapies across multiple targets
- Dyno to receive US$50 million upfront cash with the potential to earn over US$1 billion in milestones plus royalty payments
Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to enable in vivo gene delivery, today announced its second research collaboration with Roche to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases.
Dyno and Roche previously announced a research collaboration and license agreement for neurological diseases and liver-directed therapies in October 2020. Under the terms of this new collaboration, Dyno Therapeutics provides Roche further access to the company’s field-leading platform and sequence design technologies enabling in vivo gene delivery.
Existing gene therapies have primarily used a small number of naturally occurring AAV vectors limited by low delivery efficiency as well as problems with pre-existing immunity and manufacturability.
To overcome these challenges, Dyno has pioneered the application of AI and high-throughput in vivo data collection to engineering AAV capsids for improved tissue targeting, immune-evasion and manufacturability.
Dyno’s Low-Shot Efficient Accelerated Performance (LEAPSM) technology, paired with the capability to make billions of in vivo sequence-function measurements each month, enables optimization of capsids for therapeutic success at an accelerated rate.
As a platform built to solve the most critical challenges facing gene therapy developers, Dyno’s industry-leading gene delivery solutions enable Dyno partners to create ever better gene therapies.
“This new collaboration with Roche, focused on developing next-generation gene therapies for underserved patients with life-altering neurological diseases, is a testament to the outstanding progress made by Dyno’s platform and to the commitment we make to partners in all of our projects.
Our approach combines extensive in vivo data with the world’s most advanced AI models for sequence-function prediction, empowering Dyno capsid engineers with industry-leading capabilities for solving the longstanding challenge of therapeutic gene delivery. Dyno’s platform brings the entire field closer to realizing a future where all gene therapies are safe, effective, and widely accessible to all patients who need them.”
Eric Kelsic – CEO of Dyno Therapeutics
